Notice of Proposed Sale · 144

Viridian Therapeutics, Inc.

VRDNNASDAQEQUITYCurrent

Notice of Proposed Sale

Filed Aug 19, 2026Accepted Aug 19, 2026, 2:30 PM EDTFiling CIK 1590750Accession 0001959173-26-006222

View company →Permanent SEC source ↗

Structured filing — 144

primary_doc.xml

Open full document ↗

Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.

Proposed-sale notice

Issuer: Viridian Therapeutics, Inc.\DE
Issuer CIK: 0001590750
SEC file number: 001-36483
Phone: 617.272.4600
Person for whose account securities are to be sold: Tousignant Jennifer
Relationships to issuer: Officer
Street: 221 CRESCENT STREET
Street (continued): SUITE 103A
City: WALTHAM
State / country code: MA
Postal code: 02453

Securities proposed for sale

Securities proposed for sale · 1 reported row
Security	Proposed units	Aggregate market value	Units outstanding	Approximate sale date	Exchange	Broker / market maker
Common	14,212	348,194.00	113,292,269	08/19/2026	NASDAQ	Fidelity Brokerage Services LLC

Broker / market maker — proposed row 1, entry 1

Name: Fidelity Brokerage Services LLC
Street: 900 Salem Street
City: Smithfield
State / country code: RI
Postal code: 02917

Acquisition of securities to be sold

Acquisition of securities to be sold · 3 reported rows
Security	Acquired	Nature of acquisition	Acquired from	Amount acquired	Gift transaction	Payment date	Nature of payment
Common	03/03/2026	Restricted Stock Vesting	Issuer	3,494	N	03/03/2026	Compensation
Common	05/18/2026	ESPP Purchase	Issuer	718	N	05/18/2026	Cash
Common	08/19/2026	Stock Option Exercise	Issuer	10,000	N	08/19/2026	Cash

Prior-sale reporting

Nothing to report for the preceding three months: Y

Notice signature

Notice date: 08/19/2026
Signed: /s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Jennifer Tousignant

Company context

Viridian Therapeutics is a biotechnology company dedicated to developing better medicines for patients with autoimmune and rare diseases. Utilizing our expertise in antibody discovery and protein engineering, we aim to build on proven science to develop innovative medicines that address unmet needs and improve patient outcomes. With an immediate focus in thyroid eye disease (TED), we developed Lumvoa, a full IGF-1R antagonist approved by the U.S. FDA for the treatment of thyroid eye disease. We are also advancing elegrobart, a late-stage investigational subcutaneous therapy designed to further address unmet needs in TED and improve patient convenience. Beyond TED, we are advancing a pipeline of potential best-in-class medicines to address multiple serious autoimmune diseases.

Current securities

VRDNNASDAQ · EQUITY · Current

Get the free weekly BCS email.